% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Berghoff:127997,
      author       = {A. S. Berghoff and F. Wolpert and T. Holland-Letz$^*$ and
                      R. Koller and G. Widhalm and B. Gatterbauer and K. Dieckmann
                      and P. Birner and R. Bartsch and C. C. Zielinski and M.
                      Weller and M. Preusser},
      title        = {{C}ombining standard clinical blood values for improving
                      survival prediction in patients with newly diagnosed brain
                      metastases-development and validation of the {L}ab{BM}
                      score.},
      journal      = {Neuro-Oncology},
      volume       = {19},
      number       = {9},
      issn         = {1523-5866},
      address      = {Oxford},
      publisher    = {Oxford Univ. Press},
      reportid     = {DKFZ-2017-04019},
      pages        = {1255-1262},
      year         = {2017},
      abstract     = {We aimed to investigate the potential of standard
                      hematologic and serum biochemical parameters to provide an
                      independent and substantial contribution to the prediction
                      of survival in patients with newly diagnosed brain
                      metastases (BM).Hemoglobin, white blood cell count, platelet
                      count, serum albumin, creatinine, lactate dehydrogenase
                      (LDH), and C-reactive protein (CRP) were assessed at
                      diagnosis of BM in a discovery cohort of 1200 cancer
                      patients. A multivariable Cox regression model was used to
                      derive the LabBM score. The LabBM score was externally
                      validated in an independent cohort consisting of 366
                      patients.Hemoglobin below lower limit of normal (<LLN;
                      hazard ratio [HR] 1.28; P = .001), platelet count <LLN (HR:
                      1.36; P = .013), albumin <LLN (HR: 1.19; P = .038), LDH
                      above upper limit of normal (>ULN; HR: 1.51; P < .001), and
                      CRP >ULN (HR: 1.52; P < .001) were associated with survival
                      in a multivariable Cox regression model and were included in
                      the calculation of the LabBM score. Multivariable analysis
                      including the LabBM score and graded prognostic assessment
                      class revealed an independent and significant association of
                      the LabBM score with overall survival (OS) (HR: 1.42; $95\%$
                      CI: 1.29-1.57; P < .001). The strong and independent
                      association of LabBM score (HR: 1.93; $95\%$ CI: 1.54-2.42)
                      with OS prognosis was confirmed in the validation
                      cohort.Standard clinical blood parameters, combined in the
                      easy-to-calculate LabBM score, provide strong and
                      independent prognostic information in patients with BM. The
                      LabBM score is an objective, inexpensive, and reproducible
                      tool to plan clinical management strategies in BM patients
                      and to improve patient selection and stratification for
                      clinical trials.},
      cin          = {C060},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:28096493},
      pmc          = {pmc:PMC5570252},
      doi          = {10.1093/neuonc/now290},
      url          = {https://inrepo02.dkfz.de/record/127997},
}